Table 1.
Baseline characteristics of antiretroviral therapy initiation and switch during the follow-up according to the withdrawal of nelfinavir, n = 2820.
| Switch linked to NFV withdrawal | Switch not linked to NFV withdrawal | No switch | Total | P | |
|---|---|---|---|---|---|
| Baseline characteristics | |||||
| n (%) | 144 (5.1) | 188 (6.7) | 2488 (88.2) | 2820 (100.0) | 0.05 |
| Boy, n (%) | 67 (46.5) | 97 (51.6) | 1394 (56.0) | 1558 (55.2) | |
| Median age, (IQR) | 3 (2–6) | 4 (2–9) | 5 (3–9) | 5 (2–9) | <0.01 |
| First-line regimens, n (%) | <0.01 | ||||
| 2 NRTIs and 1 NNRTI | 0 (0.0) | 84 (44.7) | 1914 (76.9) | 1998 (70.9) | |
| 2 NRTIs and one PI | 144 (100.0) | 100 (53.2) | 542 (21.8) | 786 (27.9) | |
| 3 NRTIs | 0 (0.0) | 4 (2.1) | 32 (1.3) | 36 (1.3) | |
| Median CD4+ cell count (cells/μl), (IQR) | 496 (315–867) | 310 (71–578) | 393 (150–710) | 388 (148–710) | <0.01 |
| Median CD4+%, (IQR) | 15 (10–22) | 11 (4–16) | 13 (7–19) | 13 (7–19) | <0.01 |
| Immunodeficiency according to agea | <0.01 | ||||
| Severe | 71 (49.3) | 88 (46.8) | 736 (29.6) | 895 (31.7) | |
| Moderate | 21 (14.6) | 30 (16.0) | 408 (16.4) | 459 (16.3) | |
| No immunodeficiency | 15 (10.4) | 7 (3.7) | 234 (9.4) | 256 (9.1) | |
| Missing | 37 (25.7) | 63 (33.5) | 1110 (44.6) | 1210 (42.9) | |
| Severe anaemia, n (%) | <0.01 | ||||
| No | 117 (81.3) | 129 (68.6) | 1653 (66.4) | 1899 (67.3) | |
| Yes | 5 (3.5) | 12 (6.4) | 108 (4.3) | 125 (4.4) | |
| Missing | 22 (15.3) | 47 (25.0) | 727 (29.2) | 796 (28.2) | |
| Failureb during ART initiation | |||||
| Response to treatment, n (%) | <0.01 | ||||
| Clinical failure alone | 0 (0.0) | 2 (1.1) | 203 (8.2) | 205 (7.3) | |
| Immunological failure alone | 4 (2.8) | 19 (10.1) | 77 (3.1) | 100 (3.5) | |
| Clinical failure and immunological failure | 0 (0.0) | 0 (0.0) | 21 (0.8) | 21 (0.7) | |
| No clinical failure and no immunological failure | 135 (93.8) | 160 (85.1) | 1621 (65.2) | 1916 (67.9) | |
| Missing data | 5 (3.5) | 7 (3.7) | 566 (22.7) | 578 (20.5) |
ART, antiretroviral therapy; NFV, nelfinavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a
Using the 2006 WHO definition.
b
According to definitions in Materials and methods section.